Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GlaxoSmithKline PLC Remuneration Information 2021

Nov 15, 2021

5262_def-14a_2021-11-15_264dbb32-9c51-4b0e-b50a-7ed9c10996c2.html

Remuneration Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 4366S

GlaxoSmithKline PLC

15 November 2021

BLOCK LISTING SIX MONTHLY RETURN

Date: 15 November 2021

Name of applicant: GlaxoSmithKline plc
Name of scheme: GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan
Period of return: From: 1 May 2021 To: 31 October 2021
Balance of unallotted securities under scheme(s) from previous return: 35,519
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 230,000
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 265,519
Name of applicant: GlaxoSmithKline plc
Name of scheme: GlaxoSmithKline plc Share Save Plan 2012
Period of return: From: 1 May 2021 To: 31 October 2021
Balance of unallotted securities under scheme(s) from previous return: 382,466
Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 3,000,000
Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 313,319
Equals:  Balance under scheme(s) not yet issued/allotted at end of period: 3,069,147
Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRFZMMMVKKGMZM